TY - JOUR
T1 - Evidence-based treatment of Tourette’s disorder and chronic tic disorders
AU - Essoe, Joey Ka Yee
AU - Grados, Marco A.
AU - Singer, Harvey S.
AU - Myers, Nicholas S.
AU - McGuire, Joseph F.
N1 - Funding Information:
JF McGuire has received support from the Tourette Association of America, American Academy of Neurology, the Brain Research Foundation, American Psychological Foundation, and the Hilda and Preston Davis Family Foundation. He also receives royalties from Elsevier and serves as a consultant for Bracket, Syneos Health, and Luminopia. MA Grados serves as a member of the Cornelia de Lange Syndrome Foundation (CdLS) Medical Advisory Board. He also receives research/grant support from the Palo Alto Health Sciences, Inc. and the Centers of Disease Control and Prevention through the Tourette Association of America. HS Singer serves as a consultant for Cello Health BioConsulting, ClearView Healthcare Partners, Teva, Abide Therapeutics, and Trinity Partners. He receives research/grant support from the Tourette Association of America and royalties from Elsevier Inc. Dr. Essoe recieves support from the Tourette Association of America. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or conflict with the subject matter or materials discussed in this manuscript apart from those disclosed.
Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/11/2
Y1 - 2019/11/2
N2 - Introduction: Chronic Tic Disorders and Tourette’s Disorder (collectively referred to as TD) are characterized by sudden, rapid, and repetitive motor movements or vocalizations called tics. Children, adolescents, and adults with TD often experience co-occurring psychiatric symptoms and impairments in multiple domains. As a result of tics and other symptoms, patients with TD can develop negative self-views, require considerable accommodations, and experience a poor quality of life. Therefore, the efficient and effective management of TD bears considerable importance. Areas covered: This expert review evaluated the empirical support for behavioral and pharmacological interventions based on the results of randomized controlled trials (RCTs). Behavioral interventions evaluated include habit reversal training (HRT), comprehensive behavioral intervention for tics (CBIT), and exposure response prevention (ERP). Reviewed pharmacological interventions included alpha-2 agonists, antipsychotics, and anticonvulsants. Expert opinion: This review identified several efficacious behavioral and pharmacological interventions for TD. However, several gaps in the management of TD include: (1) the access/availability of behavioral interventions, (2) novel and more efficacious treatment approaches, and (3) the development of more comprehensive interventions to manage TD. In order to advance the treatment of TD, additional research is necessary to efficiently, effectively, and comprehensively develop and evaluate new treatments for patients with TD.
AB - Introduction: Chronic Tic Disorders and Tourette’s Disorder (collectively referred to as TD) are characterized by sudden, rapid, and repetitive motor movements or vocalizations called tics. Children, adolescents, and adults with TD often experience co-occurring psychiatric symptoms and impairments in multiple domains. As a result of tics and other symptoms, patients with TD can develop negative self-views, require considerable accommodations, and experience a poor quality of life. Therefore, the efficient and effective management of TD bears considerable importance. Areas covered: This expert review evaluated the empirical support for behavioral and pharmacological interventions based on the results of randomized controlled trials (RCTs). Behavioral interventions evaluated include habit reversal training (HRT), comprehensive behavioral intervention for tics (CBIT), and exposure response prevention (ERP). Reviewed pharmacological interventions included alpha-2 agonists, antipsychotics, and anticonvulsants. Expert opinion: This review identified several efficacious behavioral and pharmacological interventions for TD. However, several gaps in the management of TD include: (1) the access/availability of behavioral interventions, (2) novel and more efficacious treatment approaches, and (3) the development of more comprehensive interventions to manage TD. In order to advance the treatment of TD, additional research is necessary to efficiently, effectively, and comprehensively develop and evaluate new treatments for patients with TD.
KW - Tourette’s disorder
KW - behavior therapy
KW - comprehensive behavioral intervention for tics
KW - pharmacotherapy
KW - randomized controlled trials
UR - http://www.scopus.com/inward/record.url?scp=85073184677&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073184677&partnerID=8YFLogxK
U2 - 10.1080/14737175.2019.1643236
DO - 10.1080/14737175.2019.1643236
M3 - Review article
C2 - 31295410
AN - SCOPUS:85073184677
SN - 1473-7175
VL - 19
SP - 1103
EP - 1115
JO - Expert review of neurotherapeutics
JF - Expert review of neurotherapeutics
IS - 11
ER -